BR112022022845A2 - Tratamento de efeitos adversos causados por antipsicóticos atípicos - Google Patents

Tratamento de efeitos adversos causados por antipsicóticos atípicos

Info

Publication number
BR112022022845A2
BR112022022845A2 BR112022022845A BR112022022845A BR112022022845A2 BR 112022022845 A2 BR112022022845 A2 BR 112022022845A2 BR 112022022845 A BR112022022845 A BR 112022022845A BR 112022022845 A BR112022022845 A BR 112022022845A BR 112022022845 A2 BR112022022845 A2 BR 112022022845A2
Authority
BR
Brazil
Prior art keywords
adverse effects
effects caused
atypical antipsychotics
treatment
linker
Prior art date
Application number
BR112022022845A
Other languages
English (en)
Inventor
Sun Taolei
Original Assignee
Shenzhen Profound View Pharmaceutical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Profound View Pharmaceutical Tech Co Ltd filed Critical Shenzhen Profound View Pharmaceutical Tech Co Ltd
Publication of BR112022022845A2 publication Critical patent/BR112022022845A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Ceramic Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

TRATAMENTO DE EFEITOS ADVERSOS CAUSADOS POR ANTIPSICÓTICOS ATÍPICOS. Trata-se agrupamentos de ouro ligados por ligante e composições que compreendem os agrupamentos de ouro ligados por ligante para tratar efeitos adversos causados por antipsicóticos atípicos e fabricar um medicamento para tratamento de efeitos adversos causados por antipsicóticos atípicos. Métodos para tratar efeitos adversos causados por antipsicóticos atípicos.
BR112022022845A 2020-05-09 2020-05-09 Tratamento de efeitos adversos causados por antipsicóticos atípicos BR112022022845A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/089320 WO2021226736A1 (en) 2020-05-09 2020-05-09 Treatment of adverse effects caused by atypical antipsychotics

Publications (1)

Publication Number Publication Date
BR112022022845A2 true BR112022022845A2 (pt) 2022-12-13

Family

ID=78526045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022845A BR112022022845A2 (pt) 2020-05-09 2020-05-09 Tratamento de efeitos adversos causados por antipsicóticos atípicos

Country Status (8)

Country Link
US (1) US20230158065A1 (pt)
EP (1) EP4135721A4 (pt)
JP (1) JP2023524963A (pt)
KR (1) KR20230005888A (pt)
AU (1) AU2020448022B2 (pt)
BR (1) BR112022022845A2 (pt)
CA (1) CA3178004A1 (pt)
WO (1) WO2021226736A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023137672A1 (en) * 2022-01-20 2023-07-27 Shenzhen Profound View Pharmaceutical Technology Co., Ltd. L-n-isobutyryl cysteine (l-nibc) -bound gold cluster au 18 (l-nibc) 14, compositions and applications thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096808A1 (en) 1999-03-29 2003-05-22 Jon M. Miller Substance to prevent or reverse weight gain induced by psychoactive agents
CA2622696A1 (en) * 2007-11-05 2009-05-05 Diane Mcintosh Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
US20110021507A1 (en) 2009-07-22 2011-01-27 Theracos, Inc. Inhibiting antipsychotic-induced weight gain
US9132136B2 (en) * 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
CN111848471A (zh) * 2016-08-05 2020-10-30 深圳深见医药科技有限公司 含金团簇的物质在制备预防和治疗帕金森症药物中的应用
DK3545948T3 (da) * 2016-11-28 2021-09-20 Shenzhen Profound View Pharma Tech Co Ltd Anvendelse af guldklynger eller guld klyngeindeholdende stof i fremstilling af lægemiddel til forebyggelse og/eller behandling af glaukom
CN111568922B (zh) * 2020-05-09 2022-05-03 深圳深见医药科技有限公司 治疗非典型抗精神病药物引起的不良反应

Also Published As

Publication number Publication date
JP2023524963A (ja) 2023-06-14
US20230158065A1 (en) 2023-05-25
EP4135721A1 (en) 2023-02-22
CA3178004A1 (en) 2021-11-18
KR20230005888A (ko) 2023-01-10
EP4135721A4 (en) 2023-06-28
WO2021226736A1 (en) 2021-11-18
AU2020448022A1 (en) 2022-12-22
AU2020448022B2 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
CL2021002099A1 (es) Combinación farmacéutica que comprende tno155 y ribociclib.
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CR20190162A (es) Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
EA202091597A1 (ru) Способы и композиции для лечения апноэ сна
AR101740A1 (es) Terapia de combinación y composiciones
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BR112022015416A2 (pt) Anticorpos anti-ror1 e composições
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
BR112022004175A2 (pt) Tratamento de encefalopatia de syngap1
BR112022014435A2 (pt) Composição herbicida líquida e métodos para aumentar a atividade herbicida de composições herbicidas líquidas e para tratar o material de propagação de plantas
BR112017025263A2 (pt) método para o tratamento de doença neurológica
NI202000085A (es) Moduladores de la expresión de apol1
BR112022000956A2 (pt) Métodos de tratamento da hiperplasia adrenal congênita
BR112021022378A2 (pt) Derivado de tetraidroisoquinolina substituído como um modulador alostérico d1 positivo
BR112022022845A2 (pt) Tratamento de efeitos adversos causados por antipsicóticos atípicos
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112022012473A2 (pt) Composição de tratamento capilar, e, métodos para tratar cabelo, para melhorar a condição do cabelo e para diminuir o ph do cabelo
EA201992655A1 (ru) Применение ингибиторов белка сосудистой адгезии-1 для предотвращения или лечения мигрени
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer